B3GNT7 Antibody

What is B3GNT7 and what are its key structural characteristics?

B3GNT7 (beta-1,3-N-acetylglucosaminyltransferase 7) is an enzyme involved in glycosylation processes. In humans, the canonical protein has a reported length of 401 amino acid residues and a molecular mass of approximately 46 kDa. It belongs to the Glycosyltransferase 31 protein family and undergoes post-translational modifications, including glycosylation . The protein is also known by several synonyms including beta 1,3-N-acetylglucosaminyltransferase 7, beta-1,3-Gn-T7, beta3Gn-T7, and BGnT-7 .

B3GNT7 is an N-acetyl glucosamine (GlcNAc) transferase that catalyzes the transfer of GlcNAc via a beta1->3 linkage from UDP-GlcNAc to the non-reducing terminal galactose (Gal) in the linearly growing chain of N- and O-linked keratan sulfate proteoglycans . It cooperates with B4GALT4 galactosyltransferase and CHST6 and CHST1 sulfotransferases to construct and elongate mono- and disulfated disaccharide units within keratan sulfate polymer .

Where is B3GNT7 expressed in normal tissues?

B3GNT7 shows a specific expression pattern across tissues. It is primarily reported to be expressed in:

• Corneal epithelial cells

• Intestinal epithelial cells (notable high expression)

• Brain tissue, particularly in neuropils and perineuronal regions

• Skin tissue

• Placenta tissue

Immunohistochemical analysis using B3GNT7 antibodies has confirmed expression in human skin, colon cancer tissue, and placenta tissue . This tissue-specific expression pattern is important for researchers selecting appropriate positive control tissues for antibody validation.

What criteria should researchers use to select the appropriate B3GNT7 antibody?

When selecting a B3GNT7 antibody, researchers should consider:

• Target epitope region: Different antibodies target specific regions of B3GNT7 (N-terminal, middle region, C-terminal). For example, available antibodies include those targeting amino acids 250-300 , middle regions , or the N-terminal region.

• Applications required: Ensure the antibody is validated for your specific application. Most B3GNT7 antibodies are validated for Western Blot (WB), but if you need Immunohistochemistry (IHC) or Immunofluorescence (IF), verify application-specific validation.

• Species reactivity: Check if the antibody cross-reacts with your species of interest. Many B3GNT7 antibodies react with human and mouse samples, while some also react with rat, rabbit, dog, guinea pig, and other species .

• Conjugation requirements: Determine if you need an unconjugated antibody or one conjugated to a specific tag (e.g., FITC, APC) .

• Validation data quality: Review available validation data, including Western blot bands, IHC images, and published literature citations .

How can I validate the specificity of my B3GNT7 antibody?

A rigorous validation approach for B3GNT7 antibodies should include:

• Western blot analysis: Confirm a single band at the expected molecular weight (40-46 kDa). Use positive controls like Jurkat cells, COLO 320 cells, or mouse placenta tissue, which have been confirmed to express B3GNT7 .

• Knockout/knockdown controls: The gold standard for specificity validation is using B3GNT7 knockout tissues or knockdown cell lines. A genuine B3GNT7 antibody should show no or significantly reduced signal in these samples .

• Immunohistochemistry comparison: Compare staining patterns with published literature. For example, B3GNT7 staining should be detectable in corneal epithelial cells and brain tissue in wild-type but absent in knockout models .

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to samples. This should abolish specific signals.

• Multiple antibody validation: Use antibodies targeting different epitopes of B3GNT7 and compare the staining patterns.

What are the optimal conditions for Western blot detection of B3GNT7?

For optimal Western blot detection of B3GNT7:

• Sample preparation:

  • Use tissues with known expression (brain, placenta, cornea, intestinal samples)

  • Cell line options include Jurkat cells and COLO 320 cells

  • Include protease inhibitors in lysis buffer to prevent degradation

• Antibody dilutions:

  • Primary antibody: 1:500-1:2000 dilution is recommended for most B3GNT7 antibodies

  • Working concentration: 0.04-0.4 μg/mL for optimal signal-to-noise ratio

• Detection considerations:

  • Expected molecular weight: 40-46 kDa

  • Glycosylation of B3GNT7 may cause slight variations in the observed molecular weight

  • Extended blocking (>1 hour) may help reduce background

• Troubleshooting:

  • If multiple bands appear, try more stringent washing conditions

  • For weak signals, increase antibody concentration or extend incubation time

  • Consider using gradient gels (4-12%) for better resolution of the protein

What protocols are recommended for immunohistochemical detection of B3GNT7?

For successful immunohistochemical detection of B3GNT7:

• Tissue preparation:

  • Formalin-fixed, paraffin-embedded (FFPE) human tissues work well

  • Antigen retrieval is critical: use TE buffer pH 9.0 or alternatively citrate buffer pH 6.0

• Antibody dilutions and conditions:

  • Recommended dilution: 1:100-1:500 for IHC applications

  • For formalin-fixed tissues, some antibodies have been validated at 1:50 dilution

• Positive control tissues:

  • Human skin tissue

  • Human colon cancer tissue

  • Human placenta tissue

  • Brain tissue (cortex) for neural expression

• Signal interpretation:

  • In brain tissue, expect diffuse signals in neuropils and dense pericellular signals

  • In epithelial tissues, cytoplasmic staining with stronger Golgi-localized signal

How should I approach immunofluorescence studies using B3GNT7 antibodies?

For immunofluorescence applications:

• Protocol recommendations:

  • Working concentration: 0.25-2 μg/mL for ICC-IF applications

  • Fix cells using 4% paraformaldehyde for 15 minutes at room temperature

  • Permeabilize with 0.1% Triton X-100 for intracellular detection

• Expected localization pattern:

  • Primary localization in the Golgi apparatus

  • Use Golgi markers (e.g., GM130) for co-localization studies

  • May also show cytoplasmic vesicular pattern

• Controls and validation:

  • Include known B3GNT7-expressing cell lines as positive controls

  • Consider siRNA knockdown of B3GNT7 as negative control

  • Compare subcellular localization with published data from the Human Protein Atlas

How can B3GNT7 antibodies be used to study keratan sulfate synthesis in neural tissues?

B3GNT7 plays a critical role in keratan sulfate (KS) synthesis in neural tissues, and antibodies can be valuable tools for investigating this process:

• Experimental approach:

  • Use B3GNT7 antibodies alongside R-10G antibodies (which detect KS) in brain sections

  • Compare wild-type and B3GNT7 knockout tissues to assess dependency

  • Studies have shown that B3GNT7 is a major Beta3Gn-T required for the synthesis of R-10G-positive KS in the adult brain

• Key findings to validate:

  • In B3GNT7 knockout mice, diffuse R-10G signals in neuropils and dense pericellular signals are completely absent in the adult brain

  • This suggests that despite expression of eight Beta3Gn-T members in the brain, B3GNT7 is the predominant enzyme responsible for KS synthesis

• Methodological considerations:

  • For brain tissue analysis, use coronal sections of visual cortex or whole brain

  • Analyze expression in both neuropils and perineuronal nets (PNNs)

  • Quantify staining intensity using appropriate image analysis software

What role does B3GNT7 play in cancer research and how can antibodies help investigate this?

B3GNT7 has emerging roles in cancer biology that can be studied using antibodies:

• Research applications:

  • Analyze B3GNT7 expression levels in tumor vs. normal tissues

  • Correlate expression with clinical outcomes (overexpressed B3GNT7 has been linked to poor prognosis in breast cancer)

  • Investigate the role of B3GNT7 in cellular motility and invasion pathways

• Technical approaches:

  • Use tissue microarrays of multiple cancer types with B3GNT7 antibodies

  • Combine with markers of epithelial-mesenchymal transition

  • Perform IHC on breast cancer samples of different grades and stages

• Functional studies:

  • Manipulate B3GNT7 expression in cancer cell lines and assess phenotypic changes

  • Evaluate changes in glycosylation patterns using lectins alongside B3GNT7 antibodies

  • Investigate downstream signaling pathways affected by B3GNT7 expression

How can researchers study B3GNT7's relationship with inflammatory signaling pathways?

Recent evidence suggests B3GNT7 is regulated by inflammatory signals, particularly IL-22:

• Experimental design:

  • Treat intestinal epithelial cells with IL-22 and measure B3GNT7 expression changes

  • B3GNT7 has been identified as the glycosyltransferase gene most significantly upregulated by IL-22 treatment

  • Use B3GNT7 antibodies for Western blot and IHC to quantify these changes

• Analysis approaches:

  • Combine with antibodies against IL-22 receptor components

  • Assess temporal dynamics of B3GNT7 upregulation following cytokine stimulation

  • Investigate downstream effects on glycosylation patterns using appropriate glycan-specific antibodies

• Functional validation:

  • Use siRNA knockdown of B3GNT7 to determine if it mediates IL-22's effects on intestinal epithelial cells

  • Assess changes in polyLacNAc repeats of keratan sulfate following IL-22 treatment and B3GNT7 inhibition

What are common issues when working with B3GNT7 antibodies and how can they be resolved?

How should researchers interpret discrepancies in B3GNT7 antibody results across different samples?

When facing discrepancies in B3GNT7 antibody results:

• Consider tissue-specific expression patterns:

  • B3GNT7 expression varies significantly between tissues

  • Highest expression occurs in corneal epithelial cells, intestinal epithelial cells, and specific brain regions

  • Absence of signal in other tissues may represent genuine biological variation rather than technical issues

• Evaluate potential post-translational modifications:

  • B3GNT7 undergoes glycosylation which can vary between tissues and conditions

  • This may affect antibody recognition and apparent molecular weight (40-46 kDa range)

  • Consider using deglycosylation enzymes to determine if discrepancies are due to glycosylation differences

• Validate with alternative approaches:

  • Combine antibody-based detection with mRNA analysis (RT-PCR, RNA-Seq)

  • Use multiple antibodies targeting different epitopes of B3GNT7

  • Include knockout/knockdown controls when possible to confirm specificity

• Account for experimental variables:

  • Document fixation methods, antigen retrieval protocols, and buffer compositions

  • For IHC, try both TE buffer pH 9.0 and citrate buffer pH 6.0 for antigen retrieval

  • Statistical analysis should account for biological variation when comparing results